share_log

SVB Leerink Downgrades Calithera Biosciences to Market Perform, Lowers Price Target to $2

SVB Leerink Downgrades Calithera Biosciences to Market Perform, Lowers Price Target to $2

SVB Leerink 将Calithera Biosciences的评级下调至市场表现,将目标股价下调至2美元
Benzinga Real-time News ·  2022/11/15 04:08

SVB Leerink analyst Jonathan Chang downgrades Calithera Biosciences (NASDAQ:CALA) from Outperform to Market Perform and lowers the price target from $18 to $2.

SVB Leerink分析师乔纳森·张将Calithera Biosciences(纳斯达克股票代码:CALA)的评级从跑赢大盘下调至市场表现,并将目标股价从18美元下调至2美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发